A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR)

Fernando C. Fervenza, Pietro A. Canetta, Sean J. Barbour, Richard A. Lafayette, Brad H. Rovin, Nabeel Aslam, Michelle A. Hladunewich, Maria V. Irazabal, Sanjeev Sethi, Debbie S. Gipson, Heather N. Reich, Paul Brenchley, Matthias Kretzler, Jai Radhakrishnan, Lee A. Hebert, Patrick E. Gipson, Leslie F. Thomas, Ellen T. McCarthy, Gerald B. Appel, J. Ashley JeffersonAlfonso Eirin, John C. Lieske, Marie C. Hogan, Eddie L. Greene, John J. Dillon, Nelson Leung, John R. Sedor, Dana V. Rizk, Samuel S. Blumenthal, Lada B. Lasic, Luis A. Juncos, Dollie F. Green, James Simon, Amy N. Sussman, David Philibert, Daniel C. Cattran

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Fingerprint

Dive into the research topics of 'A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR)'. Together they form a unique fingerprint.

Medicine & Life Sciences